Want to see TSE:RVX full AI Analyst Report?
RVX Stock Chart & Stats
C$0.10
<C$0.01(5.00%)
At close: 4:00 PM EDT
C$0.10
<C$0.01(5.00%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.15
Previous CloseN/A
Volume37.12K
Average Volume (3M)27.31K
Market Cap
C$29.26M
Enterprise ValueC$139.82M
Total Cash (Recent Filing)C$79.87K
Total Debt (Recent Filing)C$77.62M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding344,286,700
10 Day Avg. Volume17,929
30 Day Avg. Volume27,310
Financial Highlights & Ratios
PEG Ratio-7.26
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Epigenetic Drug-discovery FocusA concentrated focus on small-molecule therapies targeting BET proteins gives Resverlogix a clearly defined scientific platform. This specialization can support deeper expertise and coordinated clinical development across related disease areas, although commercial success still depends on advancing candidates.
Addressable Cardiovascular And Metabolic IndicationsTargeting cardiovascular and metabolic diseases places the development program in clinically important therapeutic areas. A portfolio directed at dyslipidemia and inflammation may provide multiple avenues for product development from the same underlying approach, supporting longer-term strategic relevance.
Intellectual Property And Partnering OrientationThe company’s operating model explicitly combines clinical development and intellectual property with potential partnership or licensing routes. That structure could allow Resverlogix to seek external commercialization capabilities and funding rather than relying solely on building an internal sales organization.
Bears Say
Pre-revenue Model With Worsening LossesThe absence of revenue alongside persistent negative gross profit, EBIT, EBITDA, and worsening net losses shows that the business has not yet established a self-sustaining commercial base. Continued losses increase dependence on future financing, partnerships, or successful clinical progress.
Structural Cash ConsumptionNegative operating and free cash flow indicate that ongoing activities consume cash rather than fund themselves. The sharply negative free-cash-flow growth versus the prior annual period suggests funding needs remain material, limiting flexibility to advance programs without additional capital.
Highly Stressed Balance SheetNegative equity and debt that substantially exceeds the asset base indicate a heavily burdened capital structure. This reduces financial flexibility and elevates refinancing or dilution risk, potentially constraining clinical investment and weakening the company’s ability to absorb setbacks.
Resverlogix News
RVX FAQ
What was Resverlogix Corp. J’s price range in the past 12 months?
Resverlogix Corp. J lowest stock price was C$0.08 and its highest was C$0.15 in the past 12 months.
What is Resverlogix Corp. J’s market cap?
Resverlogix Corp. J’s market cap is C$29.26M.
When is Resverlogix Corp. J’s upcoming earnings report date?
Resverlogix Corp. J’s upcoming earnings report date is Nov 06, 2026 which is in 11 days.
How were Resverlogix Corp. J’s earnings last quarter?
Resverlogix Corp. J released its earnings results on Aug 14, 2026. The company reported -C$0.026 earnings per share for the quarter.
Is Resverlogix Corp. J overvalued?
According to Wall Street analysts Resverlogix Corp. J’s price is currently Overvalued.
Does Resverlogix Corp. J pay dividends?
Resverlogix Corp. J does not currently pay dividends.
What is Resverlogix Corp. J’s EPS estimate?
Resverlogix Corp. J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. J have?
Resverlogix Corp. J has 344,286,700 shares outstanding.
What happened to Resverlogix Corp. J’s price movement after its last earnings report?
Resverlogix Corp. J reported an EPS of -C$0.026 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Resverlogix Corp. J?
Currently, no hedge funds are holding shares in TSE:RVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Resverlogix Corp. J
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Technical Analysis
―
BriaCell Therapeutics
―
Microbix Biosystms
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―